Novartis lays off 500 pharma staff

Share this article:

Novartis is laying off up to 500 people in its Swiss pharmaceutical division and is undergoing an overall reorg that the company says will keep domestic employment at around 15,000, but which will emphasize support of 2014 launches of generic and branded drugs, reports Reuters. The company says its generics Sandoz unit will be hiring for its oncology division and for OTC manufacturing and supply chain management.

The upheaval is another in a line of recent changes for Novartis, including the January departure of its oncology head for Incyte, closing a Canadian plant in December, and a previous round of layoffs in November.

Earlier this month, there were rumors that Novartis and Merck were pondering a swap which would allow Merck to offload its OTC business, and Novartis its animal health division. Bernstein analyst Tim Anderson wrote at the time that even though it was unclear how profitable each of these divisions were, branded pharmaceuticals remain the “core focus and profit driver” of each company.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs


Reimagining healthcare? We want to hear about it.
 
Submit nominations here for MM&M's first-ever list of the Top 40 Healthcare Transformers

Email Newsletters

MM&M inVISION

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.